HLA class I-presented survivin peptide (Survivin-HLA-I)

HLA class I-presented survivin peptides are short amino acid sequences derived from the survivin protein (BIRC5) that are processed by the proteasome and displayed on the cell surface by Human Leukocyte Antigen (HLA) class I molecules. Survivin is a member of the inhibitor of apoptosis (IAP) family that is highly expressed in the vast majority of human cancers but is nearly undetectable in most terminally differentiated normal adult tissues. This differential expression makes the survivin-HLA complex an ideal target for cancer immunotherapies, including peptide vaccines, T-cell receptor (TCR) engineered T-cells, and bispecific antibodies. By targeting these specific peptide-MHC complexes, the immune system can be directed to selectively identify and eliminate malignant cells while sparing healthy tissue. Therapeutic strategies often focus on immunogenic epitopes such as the HLA-A*02:01-restricted peptides to trigger a robust cytotoxic T-lymphocyte response against the tumor.

Other names

BIRC5-derived HLA class I peptidesSurvivin-MHC class I complexSurvivin tumor-associated antigenBaculoviral IAP repeat-containing protein 5 peptides

Induction of peptide-specific cytotoxic T-lymphocyte (CTL) responses that recognize and lyse survivin-expressing tumor cells via the HLA class I presentation pathway.